APOE and hyperlipidemia: Therefore we assessed the expression levels of several known REV-ERB target genes involved in hyperlipidemia (Dhcr24, ApoE, and ApoC3) by QPCR and observed a significant decrease in these genes (S2 Fig) suggesting that SR9009 activation of REV-ERB is suppressing cholesterol and lipid metabolism but may not have efficacy in this model in which treatment started well after the development of NASH began.